UA62921C2 - A process for the synthesis of benzimidazole compound - Google Patents
A process for the synthesis of benzimidazole compound Download PDFInfo
- Publication number
- UA62921C2 UA62921C2 UA98052782A UA98052782A UA62921C2 UA 62921 C2 UA62921 C2 UA 62921C2 UA 98052782 A UA98052782 A UA 98052782A UA 98052782 A UA98052782 A UA 98052782A UA 62921 C2 UA62921 C2 UA 62921C2
- Authority
- UA
- Ukraine
- Prior art keywords
- methoxy
- dimethyl
- pyridinyl
- methyl
- differs
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 37
- -1 benzimidazole compound Chemical class 0.000 title claims description 17
- 230000015572 biosynthetic process Effects 0.000 title description 3
- 238000003786 synthesis reaction Methods 0.000 title description 3
- 239000002904 solvent Substances 0.000 claims abstract description 25
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229960000381 omeprazole Drugs 0.000 claims abstract description 24
- 238000006243 chemical reaction Methods 0.000 claims abstract description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims abstract description 12
- XURCIPRUUASYLR-UHFFFAOYSA-N Omeprazole sulfide Chemical compound N=1C2=CC(OC)=CC=C2NC=1SCC1=NC=C(C)C(OC)=C1C XURCIPRUUASYLR-UHFFFAOYSA-N 0.000 claims abstract description 10
- PSEPRWKZZJWRCB-UHFFFAOYSA-N (4-methoxy-3,5-dimethylpyridin-2-yl)methanol Chemical compound COC1=C(C)C=NC(CO)=C1C PSEPRWKZZJWRCB-UHFFFAOYSA-N 0.000 claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 45
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 32
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 22
- 239000000543 intermediate Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 4
- 230000016507 interphase Effects 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 4
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical group [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 claims description 4
- 239000012320 chlorinating reagent Substances 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- SRKVJDYNPSMHJM-UHFFFAOYSA-N 2-(chloromethyl)-4-methoxy-3,5-dimethylpyridine Chemical compound COC1=C(C)C=NC(CCl)=C1C SRKVJDYNPSMHJM-UHFFFAOYSA-N 0.000 claims description 2
- 238000002425 crystallisation Methods 0.000 claims description 2
- 230000008025 crystallization Effects 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 238000011403 purification operation Methods 0.000 claims 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 2
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 238000004140 cleaning Methods 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
- 238000000746 purification Methods 0.000 abstract description 7
- 238000002955 isolation Methods 0.000 abstract description 4
- 239000000376 reactant Substances 0.000 abstract description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 239000008346 aqueous phase Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000012071 phase Substances 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 5
- TZIHFWKZFHZASV-UHFFFAOYSA-N anhydrous methyl formate Natural products COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 4
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 4
- 239000011736 potassium bicarbonate Substances 0.000 description 4
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 4
- 235000015497 potassium bicarbonate Nutrition 0.000 description 4
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- UBOXGVDOUJQMTN-UHFFFAOYSA-N 1,1,2-trichloroethane Chemical compound ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 description 2
- ULQQGOGMQRGFFR-UHFFFAOYSA-N 2-chlorobenzenecarboperoxoic acid Chemical compound OOC(=O)C1=CC=CC=C1Cl ULQQGOGMQRGFFR-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940050176 methyl chloride Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 239000003799 water insoluble solvent Substances 0.000 description 2
- ZOQOJPGVZNGJLL-UHFFFAOYSA-N 6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-1H-benzimidazole Chemical compound N1C2=CC(OC)=CC=C2N=C1CC1=NC=C(C)C(OC)=C1C ZOQOJPGVZNGJLL-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 230000003113 alkalizing effect Effects 0.000 description 1
- 150000001348 alkyl chlorides Chemical class 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- USSBDBZGEDUBHE-UHFFFAOYSA-L magnesium;2-oxidooxycarbonylbenzoate Chemical compound [Mg+2].[O-]OC(=O)C1=CC=CC=C1C([O-])=O USSBDBZGEDUBHE-UHFFFAOYSA-L 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N methyl monoether Natural products COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9504503A SE521100C2 (sv) | 1995-12-15 | 1995-12-15 | Förfarande för framställning av en bensimidazolförening |
PCT/SE1996/001603 WO1997022603A1 (en) | 1995-12-15 | 1996-12-05 | Method for the synthesis of a benzimidazole compound |
Publications (1)
Publication Number | Publication Date |
---|---|
UA62921C2 true UA62921C2 (en) | 2004-01-15 |
Family
ID=20400614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UA98052782A UA62921C2 (en) | 1995-12-15 | 1996-05-12 | A process for the synthesis of benzimidazole compound |
Country Status (40)
Country | Link |
---|---|
US (1) | US5958955A (ko) |
EP (1) | EP0868423B1 (ko) |
JP (1) | JP3523267B2 (ko) |
KR (1) | KR100433436B1 (ko) |
CN (1) | CN1113879C (ko) |
AR (1) | AR004834A1 (ko) |
AT (1) | ATE205201T1 (ko) |
AU (1) | AU704422B2 (ko) |
CA (1) | CA2238864C (ko) |
CO (1) | CO4750654A1 (ko) |
CZ (1) | CZ288661B6 (ko) |
DE (2) | DE69615052T2 (ko) |
DK (1) | DK0868423T3 (ko) |
DZ (1) | DZ2137A1 (ko) |
EE (1) | EE03768B1 (ko) |
EG (1) | EG23859A (ko) |
ES (1) | ES2125210T3 (ko) |
HK (1) | HK1010539A1 (ko) |
HR (1) | HRP960581B1 (ko) |
HU (1) | HUP9900110A3 (ko) |
IL (1) | IL124856A (ko) |
IS (1) | IS1891B (ko) |
MA (1) | MA24026A1 (ko) |
MX (1) | MX9804603A (ko) |
MY (1) | MY115661A (ko) |
NO (1) | NO314306B1 (ko) |
NZ (1) | NZ324482A (ko) |
PL (1) | PL186132B1 (ko) |
PT (1) | PT868423E (ko) |
RU (1) | RU2166502C2 (ko) |
SE (1) | SE521100C2 (ko) |
SI (1) | SI0868423T1 (ko) |
SK (1) | SK282347B6 (ko) |
TN (1) | TNSN96148A1 (ko) |
TR (1) | TR199801070T2 (ko) |
TW (1) | TW460474B (ko) |
UA (1) | UA62921C2 (ko) |
WO (1) | WO1997022603A1 (ko) |
YU (1) | YU49420B (ko) |
ZA (1) | ZA9610067B (ko) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE521100C2 (sv) * | 1995-12-15 | 2003-09-30 | Astra Ab | Förfarande för framställning av en bensimidazolförening |
US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
US6699885B2 (en) | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
US6489346B1 (en) * | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US6645988B2 (en) | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
SK283805B6 (sk) | 1996-09-09 | 2004-02-03 | Slovakofarma, A. S. | Spôsob prípravy omeprazolu |
US6303787B1 (en) * | 1998-05-27 | 2001-10-16 | Natco Pharma Limited | Intermediates and an improved process for the preparation of Omeprazole employing the said intermediates |
SI20019A (sl) * | 1998-07-13 | 2000-02-29 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Izboljšan postopek sinteze 5-metoksi -2-/(4-metoksi-3,5-dimetil-2-piridil)metil/ sulfinil-1H-benzimidazola |
US6166213A (en) * | 1998-08-11 | 2000-12-26 | Merck & Co., Inc. | Omeprazole process and compositions thereof |
UA72748C2 (en) | 1998-11-10 | 2005-04-15 | Astrazeneca Ab | A novel crystalline form of omeprazole |
IL142703A (en) | 1998-11-10 | 2006-04-10 | Astrazeneca Ab | Crystalline form of omeprazole |
DE19951960C2 (de) * | 1999-10-28 | 2002-06-27 | Gruenenthal Gmbh | Verfahren zur Herstellung als Ulkustherapeutika geeigneter Benzimidazol-Derivate |
CA2472103A1 (en) * | 2002-01-25 | 2003-08-07 | Santarus, Inc. | Transmucosal delivery of proton pump inhibitors |
SE0203092D0 (en) * | 2002-10-18 | 2002-10-18 | Astrazeneca Ab | Method for the synthesis of a benzimidazole compound |
US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8815916B2 (en) | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
ZA200706613B (en) * | 2004-12-16 | 2009-03-25 | Cipla Ltd | Process |
CN100393712C (zh) * | 2006-01-23 | 2008-06-11 | 中国科学院成都有机化学有限公司 | 苯并咪唑型质子泵抑止剂及其前体的改进制备和分离纯化方法 |
WO2007122686A1 (ja) * | 2006-04-14 | 2007-11-01 | Eisai R & D Management Co., Ltd. | ベンズイミダゾール化合物 |
EP2125783A2 (en) * | 2007-02-21 | 2009-12-02 | Cipla Limited | Process for the preparation of esomeprazole magnesium dihydrate |
CN101492459B (zh) * | 2008-01-25 | 2011-04-27 | 山东轩竹医药科技有限公司 | 含烷氧乙酰基二氢异噁唑并吡啶化合物 |
CN101497603B (zh) * | 2008-01-30 | 2012-11-07 | 山东轩竹医药科技有限公司 | 含有被烷氧烷胺氧基取代的吡啶的苯并咪唑衍生物 |
CN103664885A (zh) * | 2013-12-12 | 2014-03-26 | 武汉工程大学 | 苯并咪唑型质子泵抑制剂中间体的制备方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US461997A (en) * | 1891-10-27 | Sand-pump or other pipes | ||
SE7804231L (sv) * | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
JPS6150978A (ja) * | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
US4619997A (en) * | 1984-09-06 | 1986-10-28 | The Upjohn Company | Substituted 2-pyridylmethylthio and sulfinyl-benzimidazoles as gastric antisecretory agents |
IL76839A (en) * | 1984-10-31 | 1988-08-31 | Byk Gulden Lomberg Chem Fab | Picoline derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same |
SE9002043D0 (sv) * | 1990-06-07 | 1990-06-07 | Astra Ab | Improved method for synthesis |
NZ244301A (en) * | 1991-09-20 | 1994-08-26 | Merck & Co Inc | Preparation of 2-pyridylmethylsulphinylbenzimidazole and pyridoimidazole derivatives from the corresponding sulphenyl compounds |
SE521100C2 (sv) * | 1995-12-15 | 2003-09-30 | Astra Ab | Förfarande för framställning av en bensimidazolförening |
-
1995
- 1995-12-15 SE SE9504503A patent/SE521100C2/sv not_active IP Right Cessation
-
1996
- 1996-05-12 UA UA98052782A patent/UA62921C2/uk unknown
- 1996-11-29 ZA ZA9610067A patent/ZA9610067B/xx unknown
- 1996-12-02 AR ARP960105459A patent/AR004834A1/es active IP Right Grant
- 1996-12-02 TN TNTNSN96148A patent/TNSN96148A1/fr unknown
- 1996-12-03 TW TW085114881A patent/TW460474B/zh not_active IP Right Cessation
- 1996-12-04 MA MA24415A patent/MA24026A1/fr unknown
- 1996-12-04 DZ DZ960182A patent/DZ2137A1/fr active
- 1996-12-04 YU YU64296A patent/YU49420B/sh unknown
- 1996-12-05 EP EP96942702A patent/EP0868423B1/en not_active Expired - Lifetime
- 1996-12-05 AU AU11550/97A patent/AU704422B2/en not_active Ceased
- 1996-12-05 DE DE69615052T patent/DE69615052T2/de not_active Expired - Fee Related
- 1996-12-05 PL PL96327334A patent/PL186132B1/pl not_active IP Right Cessation
- 1996-12-05 SK SK768-98A patent/SK282347B6/sk not_active IP Right Cessation
- 1996-12-05 KR KR10-1998-0704454A patent/KR100433436B1/ko not_active IP Right Cessation
- 1996-12-05 EE EE9800183A patent/EE03768B1/xx not_active IP Right Cessation
- 1996-12-05 IL IL12485696A patent/IL124856A/en not_active IP Right Cessation
- 1996-12-05 DE DE0868423T patent/DE868423T1/de active Pending
- 1996-12-05 ES ES96942702T patent/ES2125210T3/es not_active Expired - Lifetime
- 1996-12-05 DK DK96942702T patent/DK0868423T3/da active
- 1996-12-05 AT AT96942702T patent/ATE205201T1/de not_active IP Right Cessation
- 1996-12-05 TR TR1998/01070T patent/TR199801070T2/xx unknown
- 1996-12-05 RU RU98110659/04A patent/RU2166502C2/ru not_active IP Right Cessation
- 1996-12-05 US US08/776,222 patent/US5958955A/en not_active Expired - Lifetime
- 1996-12-05 JP JP52269797A patent/JP3523267B2/ja not_active Expired - Fee Related
- 1996-12-05 PT PT96942702T patent/PT868423E/pt unknown
- 1996-12-05 CN CN96199057A patent/CN1113879C/zh not_active Expired - Fee Related
- 1996-12-05 HU HU9900110A patent/HUP9900110A3/hu unknown
- 1996-12-05 WO PCT/SE1996/001603 patent/WO1997022603A1/en active IP Right Grant
- 1996-12-05 SI SI9630367T patent/SI0868423T1/xx unknown
- 1996-12-05 NZ NZ324482A patent/NZ324482A/xx unknown
- 1996-12-05 CZ CZ19981685A patent/CZ288661B6/cs not_active IP Right Cessation
- 1996-12-05 CA CA002238864A patent/CA2238864C/en not_active Expired - Fee Related
- 1996-12-09 HR HR960581A patent/HRP960581B1/xx not_active IP Right Cessation
- 1996-12-11 CO CO96065025A patent/CO4750654A1/es unknown
- 1996-12-13 MY MYPI96005252A patent/MY115661A/en unknown
- 1996-12-14 EG EG112296A patent/EG23859A/xx active
-
1998
- 1998-05-22 IS IS4750A patent/IS1891B/is unknown
- 1998-06-08 NO NO19982624A patent/NO314306B1/no not_active IP Right Cessation
- 1998-06-09 MX MX9804603A patent/MX9804603A/es not_active IP Right Cessation
- 1998-10-29 HK HK98111601A patent/HK1010539A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA62921C2 (en) | A process for the synthesis of benzimidazole compound | |
JP2993122B2 (ja) | オメプラゾールの合成法 | |
JP2005526049A (ja) | ベンゾイソキサゾールメタンスルホニルクロリドの調製及びゾニスアミドを形成するためのそのアミド化の方法 | |
JP2003513983A (ja) | 高純度セフポドキシムプロキセチルの製造方法 | |
CA2468426A1 (en) | Process for preparing n-(4'-cyano-3'-trifluoromethylphenyl)-3-(4"-fluorophenylsulfonyl)-2-hydroxy-2-methylpropionamide | |
WO2004039776A2 (en) | A process for the preparation of benzyl 2-oxo-4- (heteroaryl) dithio-alpha-isoprenyl-1- azetidineazetate derivatives | |
JPS5834471B2 (ja) | 化学化合物類 | |
JP3207018B2 (ja) | ベンジルコハク酸誘導体の製造方法およびその製造中間体 | |
WO2006049486A1 (en) | A PREPARATION METHOD FOR SUBSTITUTED 2-(2-PYRIDYLMETHOYLSULPHINYL)-l-H-BENZIMID AZOLES | |
JPH082865B2 (ja) | 抗潰瘍作用を有する化合物の製法 | |
US20040158072A1 (en) | Hydrates of optionally substituted 2-(2-pyridinyl) methylthio-1H-benzimidazoles and process for the production thereof | |
JPH09216872A (ja) | ジアミノピリミジン誘導体 | |
SA96170440B1 (ar) | benzimidazoleعملية لتخلق مركب بنزيميدازول | |
JPS6324994B2 (ko) | ||
JP3242253B2 (ja) | アゾアルカン誘導体の製造法 | |
CN116253715A (zh) | 一种达比加群酯中间体的制备方法 | |
EP0306936A2 (en) | Process for producing aminooxyacetic acid salts | |
KR101558960B1 (ko) | Ν-5-(4-[4-메틸-피페라지노-메틸]-벤조일아미도)-2-메틸페닐-4-[3-피리딜]-2-피리미딘-아민의 신규한 제조방법 | |
JPH01272557A (ja) | 2,6−ジエチル−4−フェノキシアリニン誘導体及びその製造法 | |
JPH05286980A (ja) | セフェム誘導体およびその製造法 | |
JPH0881427A (ja) | [[4−置換アセチル−o−フェニレン]ジオキシ]ジ酢酸誘導体及びその製造方法 | |
JPH06211796A (ja) | 3−置換キノリン−5−カルボン酸 | |
JPH01139584A (ja) | ペニシラン酸化合物の製造法 | |
JPH03161475A (ja) | テトラヒドロナフタレン誘導体の製造法 | |
JP2001278864A (ja) | 4−メトキシキノリン類の製造方法 |